Your session is about to expire
← Back to Search
Dietary Supplement
Enterade for Neuroendocrine Tumors
N/A
Waitlist Available
Led By Satya Das, MD
Research Sponsored by Vanderbilt-Ingram Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at 8 weeks
Awards & highlights
No Placebo-Only Group
Summary
This is an open-label phase II basket study evaluating the ability of enterade® to reduce bowel frequency in neuroendocrine tumor (NET) patients with carcinoid syndrome and non-carcinoid syndrome.
Eligible Conditions
- Neuroendocrine Tumors
- Carcinoid Syndrome
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ at 8 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at 8 weeks
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Change in bowel movement frequency
Secondary study objectives
Change in serum electrolytes (Chloride)
Change in serum electrolytes (Magnesium)
Change in serum electrolytes (Phosphorous)
+10 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Group I: ExperimentalExperimental Treatment2 Interventions
Non-Carcinoid Syndrome: Participants will drink a bottle of Enterade two time per day for 4 weeks.
Group II: EnteradeExperimental Treatment2 Interventions
Carcinoid Syndrome: Participants will drink a bottle of Enterade two time per day for 4 weeks.
Find a Location
Who is running the clinical trial?
Vanderbilt-Ingram Cancer CenterLead Sponsor
217 Previous Clinical Trials
63,545 Total Patients Enrolled
4 Trials studying Neuroendocrine Tumors
113 Patients Enrolled for Neuroendocrine Tumors
Entrinsic Bioscience Inc.Industry Sponsor
7 Previous Clinical Trials
761 Total Patients Enrolled
1 Trials studying Neuroendocrine Tumors
10 Patients Enrolled for Neuroendocrine Tumors
Satya Das, MDPrincipal InvestigatorVanderbilt-Ingram Cancer Center
Share this study with friends
Copy Link
Messenger